References

  1. Gillam Mary P, Molitch Mark E, Lombardi Gaetano, Colao Annamaria. Advances in the treatment of prolactinomas. Endocr Rev. 2006; 27(5): 485-534. PubMed | Google Scholar

  2. Mindermann Thomas, Wilson Charles B. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf). 1994; 41(3): 359–64. PubMed | Google Scholar

  3. Fideleff HL, Boquete HR, Suárez MG, Azaretzky M. Prolactinoma in children and adolescents. Horm Res. 2009; 72(4): 197–205. PubMed | Google Scholar

  4. Shimon Ilan, Bronstein Marcello D, Shapiro Jonathan, Tsvetov Gloria, Benbassat Carlos, Barkan Ariel. Women with prolactinomas presented at the postmenopausal period. Endocrine. 2014; 47(3): 889–94. PubMed | Google Scholar

  5. Mazziotti G, Mancini T, Mormando M, De Menis E, Bianchi A, Doga M, Porcelli T, Vescovi PP, De Marinis L, Giustina A. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. 2011; 14(4): 299-306. PubMed | Google Scholar

  6. Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 2013 ;73(15): 4810-9. PubMed | Google Scholar

  7. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006; 91(12): 4769-75. PubMed | Google Scholar

  8. Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012; 167(5): 651-62. PubMed | Google Scholar

  9. Scoccia B, Schneider AB, Marut EL, Scommegna A. Pathological hyperprolactinemia suppresses hot flashes in menopausal women. J Clin Endocrinol Metab. 1988; 66(4): 868–71. PubMed | Google Scholar

  10. Cramer OM, Parker CR Jr, Porter JC. Secretion of dopamine into hypophysial portal blood by rats bearing prolactin-secreting tumors or ectopic pituitary glands. Endocrinology. 1979; 105(3): 636-40. PubMed | Google Scholar

  11. Meldrum DR, Erlik Y, Lu JK, Judd HL.Objectively recorded hot flushes in patients with pituitary insufficiency.J Clin Endocrinol Metab.1981; 52(4): 684-8. PubMed | Google Scholar

  12. Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J Cell Biochem. 2009; 107(4): 677–85. PubMed | Google Scholar

  13. Touraine P. Implication de la prolactine dans le cancer du sein. Médecine Thérapeutique Endocrinol. 2001; 3: 161–71. Google Scholar

  14. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf). 1998; 48(5): 547–53. PubMed | Google Scholar

  15. Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol. 2006 May; 154(5): 753-8. PubMed | Google Scholar

  16. Faje AT, Klibanski A. The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: Cons. Endocrine. 2015; 48(1): 79-82. PubMed | Google Scholar

  17. Iacovazzo D, De Marinis L. Treatment of hyperprolactinemia in post-menopausal women: pros. Endocrine. 2015 Feb; 48(1): 76-8. PubMed | Google Scholar